BR112022002029A2 - Uso de sepiapterina e seus metabólitos para tratar exposição à radiação - Google Patents

Uso de sepiapterina e seus metabólitos para tratar exposição à radiação

Info

Publication number
BR112022002029A2
BR112022002029A2 BR112022002029A BR112022002029A BR112022002029A2 BR 112022002029 A2 BR112022002029 A2 BR 112022002029A2 BR 112022002029 A BR112022002029 A BR 112022002029A BR 112022002029 A BR112022002029 A BR 112022002029A BR 112022002029 A2 BR112022002029 A2 BR 112022002029A2
Authority
BR
Brazil
Prior art keywords
sepiapterin
radiation exposure
metabolites
treat radiation
treat
Prior art date
Application number
BR112022002029A
Other languages
English (en)
Inventor
Christopher Rabender
Eleonora Mezzaroma
Neil Smith
Ross Mikkelsen
Vasily Yakovlev
Original Assignee
Ptc Therapeutics Mp Inc
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Mp Inc, Univ Virginia Commonwealth filed Critical Ptc Therapeutics Mp Inc
Publication of BR112022002029A2 publication Critical patent/BR112022002029A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

uso de sepiapterina e seus metabólitos para tratar exposição à radiação. a presente invenção refere-se a métodos para tratar a exposição à radiação em um indivíduo através da administração de sepiapterina, tetra-hidrobiopterina ou di-hidrobiopterina.
BR112022002029A 2019-08-05 2020-08-05 Uso de sepiapterina e seus metabólitos para tratar exposição à radiação BR112022002029A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962882937P 2019-08-05 2019-08-05
PCT/US2020/045026 WO2021026247A1 (en) 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure

Publications (1)

Publication Number Publication Date
BR112022002029A2 true BR112022002029A2 (pt) 2022-06-07

Family

ID=72148243

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022002029A BR112022002029A2 (pt) 2019-08-05 2020-08-05 Uso de sepiapterina e seus metabólitos para tratar exposição à radiação

Country Status (10)

Country Link
US (1) US20220273661A1 (pt)
EP (1) EP4009978A1 (pt)
JP (1) JP2022543655A (pt)
CN (1) CN114555090A (pt)
AU (1) AU2020324435A1 (pt)
BR (1) BR112022002029A2 (pt)
CA (1) CA3146477A1 (pt)
IL (1) IL290321A (pt)
MX (1) MX2022001535A (pt)
WO (1) WO2021026247A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
JP2020532535A (ja) 2017-09-01 2020-11-12 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
AU2019277382A1 (en) 2018-05-30 2021-01-21 Ptc Therapeutics Mp, Inc. Methods for increasing sepiapterin plasma exposure

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
TWI359019B (en) * 2006-08-14 2012-03-01 Merck Eprova Ag Use of folates for the prevention and treatment of
CA3043499A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
JP2020532535A (ja) 2017-09-01 2020-11-12 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
CN112543758A (zh) 2018-05-30 2021-03-23 Ptc医疗Mp公司 墨蝶呤的药学上可接受的盐
CN110354133A (zh) * 2019-08-26 2019-10-22 鞍山市肿瘤医院 四氢生物蝶呤的应用及药物

Also Published As

Publication number Publication date
AU2020324435A1 (en) 2022-02-24
CN114555090A (zh) 2022-05-27
MX2022001535A (es) 2022-03-04
EP4009978A1 (en) 2022-06-15
CA3146477A1 (en) 2021-02-11
WO2021026247A1 (en) 2021-02-11
US20220273661A1 (en) 2022-09-01
JP2022543655A (ja) 2022-10-13
IL290321A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
BR112022002029A2 (pt) Uso de sepiapterina e seus metabólitos para tratar exposição à radiação
CO2019007298A2 (es) Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos
PE20200494A1 (es) Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112020003865A8 (pt) Composições farmacêuticas compreendendo sepiapterina e seus usos
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
BR112017001162A2 (pt) métodos para tratar paramixovírus
BR112015018094A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
BR112016000489A8 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
BR112015018087A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
BR112015018089A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
BR112015021979A2 (pt) Anticorpos humanos para grem1
BR112014011925A2 (pt) mutações no receptor notch humano e seu uso
BR112021008873A8 (pt) Formulação
BR112017018160A2 (pt) uso do vírus vaccinia ankara modificado (mva) não replicante inativado como monoimunoterpia ou em combinação com agentes de bloqueio de pontos de verificação imunológica para tumores sólidos
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112021016833A2 (pt) Compostos com atividade indutora de ferroptose e métodos de seu uso
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112015027474A8 (pt) anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo.
CO2020014599A2 (es) Métodos para tratar cáncer
MX2021001612A (es) Compuestos utiles en terapia del vih.
BR112022010702A2 (pt) Macrociclos para uso no tratamento de doenças
BR112019016839A2 (pt) tratamentos de combinação que compreendem a administração de 1h-pirazolo[4,3-b] piridinas
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
BR112019025611A2 (pt) Derivados de xantina substituídos